Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

(2011) Keyvan Rezai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Matthias Scheffler et al.   CLINICAL PHARMACOKINETICS

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis

(2010) C. A. Harris et al.   ANNALS OF ONCOLOGY

Mechanism-Based Inactivation of Cytochrome P450 3A4 by Lapatinib

(2010) W. C. Teng et al.   MOLECULAR PHARMACOLOGY

1229 A phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors

(2009) H. Chew et al.   EJC SUPPLEMENTS

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

(2008) H. J. Burstein et al.   ANNALS OF ONCOLOGY

Her2-positive breast cancer: Herceptin and beyond

(2008) Windy Dean-Colomb et al.   EUROPEAN JOURNAL OF CANCER